René Reitermaier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
René Reitermaier has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Adelheid Elbe-Bürger
Medical University of Vienna
24 shared publications - Wolfgang Weninger
Department of Dermatology, Medical University of Vienna, Vienna, Austria
22 shared publications - Alexander Leitner
Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland
21 shared publications - Andrea Bileck
Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria
21 shared publications - Bernd Wollscheid
Department of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
21 shared publications - Betty Friedrich
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
21 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in International Journal of Pharmaceutics: X
Glycosylation-dependent binding of the peanut allergen Ara h 1 to CD207 and uptake by human Langerhans cells
- 13 November 2026
- Published by Elsevier in International Journal of Pharmaceutics: X
Open AccessGlycosylation-dependent binding of the peanut allergen Ara h 1 to CD207 and uptake by human Langerhans cells
- Open Access
- 5 September 2026
- Published by Elsevier in SSRN Electronic Journal
Glycosylation-dependent uptake of the major peanut allergen Ara h 1 by human skin Langerhans cells
Background: Acute peanut-allergic reactions often occur early in life and may follow first known ingestion, indicating that sensitization can precede gastrointestinal exposure. Cutaneous exposure through a disrupted skin barrier is considered an important route of primary sensitization. Langerhans cells (LCs), immune sentinels of stratified epithelia, may contribute to this process.Objective: To characterize peanut-allergen uptake by human LCs and its functional consequences.Methods: Uptake of Alexa Fluor 488-labelled natural Ara h 1 and Ara h 2 was assessed in a human skin explant model and MUTZ-3-derived LC-like cells. Binding of glycosylated and deglycosylated allergens to selected C-type lectin receptors (CLRs) was examined by CLR-based ELISA. For functional analysis, allergen-exposed primary LCs emigrating from human epidermal sheets were co-cultured with allogeneic naive CD4⁺ T cells, followed by multiplex cytokine analysis.Results: Natural Ara h 1 was internalized by resident LCs in barrier-disrupted ex vivo skin and by MUTZ-3-derived LC-like cells in a time- and concentration-dependent manner. Blocking CD207 significantly reduced Ara h 1 uptake. CLR-based ELISA demonstrated glycosylation-dependent binding of Ara h 1 to CD207 Ara h 1-exposed primary LCs induced modest but significant increases in IL-5 and IL-13 production by CD4⁺ T cells, whereas Ara h 2 had no significant effect.Conclusion: By identifying glycan-dependent recognition of Ara h 1 by CD207-expressing LCs as a mechanism of allergen uptake and demonstrating that Ara h 1-exposed LCs promote Th2-associated T cell responses, this study provides mechanistic and functional insight into how human LCs may contribute to peanut sensitization through barrier-disrupted skin.
- 5 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGlycosylation-dependent uptake of the major peanut allergen Ara h 1 by human skin Langerhans cells
Background: Acute peanut-allergic reactions often occur early in life and may follow first known ingestion, indicating that sensitization can precede gastrointestinal exposure. Cutaneous exposure through a disrupted skin barrier is considered an important route of primary sensitization. Langerhans cells (LCs), immune sentinels of stratified epithelia, may contribute to this process.Objective: To characterize peanut-allergen uptake by human LCs and its functional consequences.Methods: Uptake of Alexa Fluor 488-labelled natural Ara h 1 and Ara h 2 was assessed in a human skin explant model and MUTZ-3-derived LC-like cells. Binding of glycosylated and deglycosylated allergens to selected C-type lectin receptors (CLRs) was examined by CLR-based ELISA. For functional analysis, allergen-exposed primary LCs emigrating from human epidermal sheets were co-cultured with allogeneic naive CD4⁺ T cells, followed by multiplex cytokine analysis.Results: Natural Ara h 1 was internalized by resident LCs in barrier-disrupted ex vivo skin and by MUTZ-3-derived LC-like cells in a time- and concentration-dependent manner. Blocking CD207 significantly reduced Ara h 1 uptake. CLR-based ELISA demonstrated glycosylation-dependent binding of Ara h 1 to CD207 Ara h 1-exposed primary LCs induced modest but significant increases in IL-5 and IL-13 production by CD4⁺ T cells, whereas Ara h 2 had no significant effect.Conclusion: By identifying glycan-dependent recognition of Ara h 1 by CD207-expressing LCs as a mechanism of allergen uptake and demonstrating that Ara h 1-exposed LCs promote Th2-associated T cell responses, this study provides mechanistic and functional insight into how human LCs may contribute to peanut sensitization through barrier-disrupted skin.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Primary melanoma tumor cells of NR display a distinctive immunophenotype.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Primary melanoma tumor cells of NR display a distinctive immunophenotype.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Enlarged proteomaps results for the tumor cell lysate dataset.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Enlarged proteomaps results for the tumor cell lysate dataset.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Statistical analysis of baseline clinical parameters in the serum discovery cohort (n=56).
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Statistical analysis of baseline clinical parameters in the serum discovery cohort (n=56).
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Statistical analysis of baseline clinical parameters in the independent Zurich serum validation cohort A (n=80).
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Statistical analysis of baseline clinical parameters in the independent Zurich serum validation cohort A (n=80).
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Differentially expressed proteins (DEPs) in NR of the discovery serum and tumor cell cohorts.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Differentially expressed proteins (DEPs) in NR of the discovery serum and tumor cell cohorts.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Antibodies used for immunofluorescence staining on a melanoma tissue microarray (TMA).
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Antibodies used for immunofluorescence staining on a melanoma tissue microarray (TMA).
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Antibodies used for immunofluorescence staining on a melanoma tissue microarray (TMA).
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Antibodies used for immunofluorescence staining on a melanoma tissue microarray (TMA).
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Results of the Wilcoxon rank sum tests, dependent variable = first component of the PCA.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Results of the Wilcoxon rank sum tests, dependent variable = first component of the PCA.